US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capstone Therapeutics Corp

1.67

-0.0300-1.76%

Post-market: 1.670.00000.00%16:46 EDT

Volume:8.07K

Turnover:13.79K

Market Cap:8.67M

PE:-1.47

High:1.72

Open:1.70

Low:1.67

Close:1.70

Loading ...

Overview Company News Filings

Capstone Therapeutics Expands Stock Purchase Agreement with Equity Line Investor, Increases Purchase Limit to $3 Million

Capstone Therapeutics Corporation Expands into Mountain States with $1 Million Pangaea Stone Order, Marking Major Growth Milestone

Top Premarket Decliners

MT Newswires Live

Capstone Reaffirms 2025 Revenue Run-Rate of $100 Million

MT Newswires Live

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

APRIL HARVARD CAPS / HARRIS POLL: OVERALL TRUMP JOB APPROVAL REMAINS NET POSITIVE WITH 48% APPROVING, 46% DISAPPROVING

Capstone Targets Growth in Southeast, Identifies Key Acquisition Candidates

ACCESS Newswire

Capstone Targets $100M Run Rate Increases Q4 Revenue and Executes Strategic Brand Expansion

ACCESS Newswire

EXCLUSIVE: Capstone Clocks 8% Q4 Revenue Growth, Aims For $100 Million Revenue Run Rate By 2025

Capstone Sees Minimal Effect from China Tariffs, Decrease in Container Prices Offsets Tariffs

ACCESS Newswire

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution

Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CAPS/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CAPS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAPS\",,,,,undefined,":{"symbol":"CAPS","market":"US","secType":"STK","nameCN":"Capstone Therapeutics Corp","latestPrice":1.67,"timestamp":1751054400000,"preClose":1.7,"halted":0,"volume":8074,"hourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.67,"latestTime":"16:46 EDT","volume":166,"amount":277.22,"timestamp":1751057164220},"delay":0,"floatShares":1719687,"shares":5190251,"eps":-1.13559,"marketStatus":"Market Closed","change":-0.03,"latestTime":"06-27 16:00:00 EDT","open":1.7,"high":1.72,"low":1.67,"amount":13792.820659199999,"amplitude":0.029412,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.13559,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.7,"preHourTrading":{"tag":"盘前","latestPrice":1.7,"preClose":1.77,"latestTime":"08:19 EDT","volume":9,"amount":15.1399989,"timestamp":1751026764739},"postHourTrading":{"tag":"盘后","latestPrice":1.67,"preClose":1.67,"latestTime":"16:46 EDT","volume":166,"amount":277.22,"timestamp":1751057164220},"volumeRatio":0.3228257033452358},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CAPS\",,,,,undefined,":{"symbol":"CAPS","floatShares":1719687,"roa":"-0.80%","roe":"-9.21%","lyrEps":-34.864539,"volumeRatio":0.3228257033452358,"shares":5190251,"dividePrice":0,"high":1.72,"amplitude":0.029412,"preClose":1.7,"low":1.67,"week52Low":1.58,"pbRate":"0.32","psRate":"0.20","week52High":16.18,"institutionHeld":0.0002,"latestPrice":1.67,"eps":-1.13559,"divideRate":0,"volume":8074,"delay":0,"ttmEps":-1.13559,"open":1.7,"prevYearClose":2.24,"prevWeekClose":1.76,"prevMonthClose":1.82,"prevQuarterClose":2.41,"fiveDayClose":1.76,"twentyDayClose":1.8,"sixtyDayClose":2.34},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CAPS\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2546674590","title":"Capstone Therapeutics Expands Stock Purchase Agreement with Equity Line Investor, Increases Purchase Limit to $3 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2546674590","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546674590?lang=en_us&edition=fundamental","pubTime":"2025-06-27 20:31","pubTimestamp":1751027473,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation has entered into a significant stock purchase agreement with an accredited investor, involving the potential sale of up to $20 million in common stock. Under the terms of this agreement, Capstone has the option to sell shares to the investor, priced at 97% of the lowest daily volume-weighted average price over a three-day period. Additionally, a recent amendment to this agreement has increased the limits on the volume and dollar amount of shares that can be purchased in a single transaction. This amendment allows for a maximum purchase of up to 40% of the trading volume or $3 million, whichever is lower, enhancing Capstone's financial flexibility and capital-raising options.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investmen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250627:nNDL86gFXM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","BK4139","CAPS"],"gpt_icon":0},{"id":"2544609529","title":"Capstone Therapeutics Corporation Expands into Mountain States with $1 Million Pangaea Stone Order, Marking Major Growth Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2544609529","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544609529?lang=en_us&edition=fundamental","pubTime":"2025-06-17 21:12","pubTimestamp":1750165930,"startTime":"0","endTime":"0","summary":"Capstone Therapeutics Corporation Expands into Mountain States with $1 Million Pangaea Stone Order, Marking Major Growth Milestone. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Capstone Therapeutics Corporation published the original content used to generate this news brief via ACCESS Newswire  on June 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDLYgrRC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4104","BK4139"],"gpt_icon":0},{"id":"2536689361","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2536689361","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2536689361?lang=en_us&edition=fundamental","pubTime":"2025-05-19 19:53","pubTimestamp":1747655634,"startTime":"0","endTime":"0","summary":"Mainz Biomed  shares fell 18% pre-bell Monday following a 6.6% increase in the previous session.Forte Biosciences  shares dropped 15% following a muted session.Capstone Holding  stock was down 13%, paring gains from Friday.Lichen International  shares retreated 12%, cutting Friday's rally.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["MYNZ","BK7145","BK4139","FBRX","BK4123","LICN","LICN.AU","BK4104","CAPS"],"gpt_icon":0},{"id":"2535520397","title":"Capstone Reaffirms 2025 Revenue Run-Rate of $100 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2535520397","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535520397?lang=en_us&edition=fundamental","pubTime":"2025-05-16 20:48","pubTimestamp":1747399732,"startTime":"0","endTime":"0","summary":"Capstone (CAPS) said Friday it reaffirmed its 2025 revenue run-rate target of $100 million, and $10 million in adjusted earnings before interest, taxes, depreciation and amortization, driven by organi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CAPS"],"gpt_icon":0},{"id":"2531346782","title":"Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2531346782","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531346782?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:30","pubTimestamp":1745926200,"startTime":"0","endTime":"0","summary":"– ARCALYST  Q1 2025 net product revenue of $137.8 million, representing 75% year-over-year growth –– ARCALYST 2025 expected net product revenue increased to $590 - $605 million –– KPL-387 Phase 2/3 clinical trial in recurrent pericarditis on track to initiate in mid-2025; Phase 2 data expected in 2H 2026 –– Current operating plan expected to remain cash flow positive on an annual basis –– Conference call and webcast scheduled for 8:30 am ETtoday–。LONDON, April 29, 2025  -- Kiniksa Pharmaceuticals International, plc  , a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported first quarter 2025 financial results and recent portfolio execution.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kiniksa-pharmaceuticals-reports-first-quarter-113000105.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4505","BK4139","KNSA","CAPS"],"gpt_icon":0},{"id":"2527861113","title":"APRIL HARVARD CAPS / HARRIS POLL: OVERALL TRUMP JOB APPROVAL REMAINS NET POSITIVE WITH 48% APPROVING, 46% DISAPPROVING","url":"https://stock-news.laohu8.com/highlight/detail?id=2527861113","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527861113?lang=en_us&edition=fundamental","pubTime":"2025-04-15 00:32","pubTimestamp":1744648320,"startTime":"0","endTime":"0","summary":"51% OF VOTERS APPROVE OF TRUMP'S JOB ON IMMIGRATION AND 41% ON TARIFFS AND INFLATION. VOTERS SPLIT ON TRUMP'S TARIFFS BUT 48% SAY THEY NEED MORE TIME TO WORK. OVERWHELMING SUPPORT FOR FREE TRADE BUT 58% VIEW CHINA AND OTHER COUNTRIES AS TAKING ADVANTAGE OF THE U.S. WITH UNFAIR TRADE PRACTICES. 78% OF VOTERS SUPPORT REDUCING GOVERNMENT EXPENDITURES BUT WOULD NOT RENEW MUSK PAST 6 MONTHS. 60% OF VOTERS FAVOR DIRECT NEGOTIATIONS WITH IRAN WHILE 71% FAVOR OUTRIGHT DESTRUCTION OF IRAN NUCLEAR WEAPONS FACILITIES. NEW YORK and CAMBRIDGE, Mass., April 14, 2025 /PRNewswire/ -- Stagwell today released the results of the April Harvard CAPS / Harris poll, a monthly collaboration between the Center for American Political Studies at Harvard  and the Harris Poll and HarrisX.INFLATION AND THE ECONOMY REMAIN TOP ISSUES FOR VOTERS. 39% of voters say the country is on the right track, down 2 points from March 2025 .The Democratic Party's approval rating has bounced back to November 2024 levels at 42%  bu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/april-harvard-caps-harris-poll-163200009.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/april-harvard-caps-harris-poll-163200009.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4554","NET","JOB","BK4588","STGW","BK4613","BK4607","BK4548","BK4560","BK4585","BK4139","LU1169590202.USD","BK4130","LU2286300806.USD","BK4116","LU1169589451.USD","CAPS","BK4009"],"gpt_icon":1},{"id":"2526729367","title":"Capstone Targets Growth in Southeast, Identifies Key Acquisition Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2526729367","media":"ACCESS Newswire","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526729367?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:00","pubTimestamp":1744203600,"startTime":"0","endTime":"0","summary":"Management has identified 1500+ targets to bolster operations. ALSIP, IL / ACCESS Newswire / April 9, 2025 / Capstone Holding Corp. , , a national building products distribution company with a track record of both organic growth and well-timed acquisitions is pursuing opportunities in the Southeast U.S - a region with over 1,500 acquisition candidates.In today's uncertain economic climate-marked by persistent inflation, high interest rates, and shifting policy-Capstone sees a unique window to accelerate growth through strategic M&A.Matt Lipman, CEO of Capstone, stated, \"Navigating this environment requires scale, infrastructure, and operational discipline. Our Instone platform offers exactly that. Owners and operators increasingly recognize that partnering with Capstone provides the foundation to grow, adapt, and preserve their legacy.\". Lipman continued, \"We are focused on acquiring building products distribution companies in the Southeast, where our team is already on the ground and ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/capstone-targets-growth-southeast-identifies-130000756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CAPS"],"gpt_icon":0},{"id":"2524114786","title":"Capstone Targets $100M Run Rate Increases Q4 Revenue and Executes Strategic Brand Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=2524114786","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524114786?lang=en_us&edition=fundamental","pubTime":"2025-04-01 21:00","pubTimestamp":1743512400,"startTime":"0","endTime":"0","summary":"ALSIP, ILLINOIS / ACCESS Newswire / April 1, 2025 / Capstone Holding Corp. , , a national building products distribution company that has successfully grown its business organically and through well-timed acquisitions, announced financial results for the full year ended December 31, 2024.\"I'm proud of the team's execution and focus on growth in the second half of the year. As the parent company, our mission is clear: double the size of the business through targeted, strategic acquisitions - and we believe we're well on our way. We remain focused on scaling efficiently.\". The Company is targeting an operating company revenue run rate by the end of 2025 of $100 million and Adjusted Instone EBITDA of at least $10 million.1. Kevin Grotke, CEO of TotalStone, LLC , a wholly owned operating subsidiary of Capstone and its primary business activity, said,This announcement contains forward-looking statements. These statements are made under the \"safe harbor\" provisions of the U.S. Private Securi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/capstone-targets-100m-run-rate-130000114.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAPS"],"gpt_icon":0},{"id":"2524511309","title":"EXCLUSIVE: Capstone Clocks 8% Q4 Revenue Growth, Aims For $100 Million Revenue Run Rate By 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524511309","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524511309?lang=en_us&edition=fundamental","pubTime":"2025-04-01 20:30","pubTimestamp":1743510626,"startTime":"0","endTime":"0","summary":"Capstone Holding Corp (CAPS) announced its Q4 results with 8% revenue growth, successful launch of Toro Stone, and plans for strategic acquisitions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/04/44583827/exclusive-capstone-clocks-8-q4-revenue-growth-aims-for-100-million-revenue-run-rate-by-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS"],"gpt_icon":0},{"id":"2520455298","title":"Capstone Sees Minimal Effect from China Tariffs, Decrease in Container Prices Offsets Tariffs","url":"https://stock-news.laohu8.com/highlight/detail?id=2520455298","media":"ACCESS Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520455298?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:45","pubTimestamp":1742471100,"startTime":"0","endTime":"0","summary":"ALSIP, IL / ACCESS Newswire / March 20, 2025 / Capstone Holding Corp , a building products holding company growing organically and by acquisition, has seen tariffs on its products imported from China increase in line with presidential orders. However, since the beginning of the year prices of containers from China to the USA have declined between 15% to 25%.As Kevin Grotke, CEO of the Instone operating business explained, \"There is a fair amount of freight in our products and only the product cost is subject to tariff. So a 10% tariff typically will create a price increase to the customer of 3%-4%. With a 15% to 25% decline in container pricing, the tariffs as currently constructed are offset by decreased shipping costs.\". Matt Lipman CEO of Capstone Holding added \"Kevin and his team have continued to demonstrate that the company has a nimble supply chain that was battle tested through Covid and the first Trump Administration's tariff regime. Despite the recent economic rhetoric, as in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/capstone-sees-minimal-effect-china-114500671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CAPS","BK4139"],"gpt_icon":0},{"id":"2514095741","title":"Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095741","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095741?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:30","pubTimestamp":1740486600,"startTime":"0","endTime":"0","summary":"– ARCALYST (rilonacept) Q4 2024 and full year 2024 net product revenue of $122.5 million and $417.0 million, respectively –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– KPL","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/25/3031905/0/en/Kiniksa-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results-and-Recent-Portfolio-Execution.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4139"],"gpt_icon":0},{"id":"2514095702","title":"Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514095702","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514095702?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:29","pubTimestamp":1740486540,"startTime":"0","endTime":"0","summary":"– Kiniksa plans to initiate a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis in mid-2025 –。– KPL-387 Phase 1 single ascending dose data support potential monthly dosing –。– Kiniksa continues to focus development on diseases with unmet need, prioritizing cardiovascular indications –。– Kiniksa to discontinue abiprubart development in Sjgren’s Disease –。“Through the successful development and commercialization of ARCALYST, Kiniksa has helped thousands of patients suffering from recurrent pericarditis. Since the launch in 2021, we have generated over $800 million in product revenue and have become cash flow positive on an annual basis. We plan to further increase our penetration into the recurrent pericarditis population with ARCALYST,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “We also continue to focus development on novel therapies for diseases with unmet need, prioritizing cardiovascular indications. Today, we are excited to extend our leadersh","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kiniksa-pharmaceuticals-announces-development-kpl-122900481.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4600","BK4585","MSTR","BK4516","KNSA","STRK","BK4595","BK4596","CAPS","MSTU","BK4505","BK4023","BK4139","BK4588"],"gpt_icon":0},{"id":"2503306874","title":"Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2503306874","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503306874?lang=en_us&edition=fundamental","pubTime":"2025-01-13 20:30","pubTimestamp":1736771400,"startTime":"0","endTime":"0","summary":"– ARCALYST (rilonacept) 2024 net product revenue of $416.4 million (unaudited), representing ~79% year-over-year growth –– ARCALYST 2025 net product revenue expected to be $560 - $580 million –– Kinik","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/13/3008362/0/en/Kiniksa-Pharmaceuticals-Reports-Preliminary-2024-Net-Product-Revenue-and-Provides-2025-Net-Product-Revenue-Guidance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAPS","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":13,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CAPS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-04-01","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1743480000000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2020-08-05","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1596600000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-05-07","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1588824000000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2020-02-07","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1581051600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2019-11-11","symbol":"CAPS","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1573448400000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CAPS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CAPS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1743739200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CAPS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CAPS","date":"2025-06-27","current":-2.776408,"percent":0.974026,"low":-5.872699,"twenty":-4.298631,"median":-3.589901,"eighty":-3.086713,"high":-2.566034,"avg":-3.740435,"sd":0.737457,"marketCap":8823426},"quantilePoints":[{"date":"2025-03-05","current":-5.669144,"twenty":-5.669144,"median":-5.669144,"eighty":-5.669144,"marketCap":19722953},{"date":"2025-03-14","current":-3.759538,"twenty":-4.953042,"median":-4.565153,"eighty":-4.47564,"marketCap":13079432},{"date":"2025-03-21","current":-3.177705,"twenty":-4.639747,"median":-4.445803,"eighty":-3.311974,"marketCap":11055234},{"date":"2025-03-28","current":-3.7297,"twenty":-4.490559,"median":-4.154886,"eighty":-3.311974,"marketCap":12975627},{"date":"2025-04-04","current":-4.212143,"twenty":-4.639747,"median":-4.177264,"eighty":-3.580512,"marketCap":10795722},{"date":"2025-04-11","current":-4.897426,"twenty":-4.779162,"median":-4.194704,"eighty":-3.595431,"marketCap":12552103},{"date":"2025-04-17","current":-4.4349,"twenty":-4.908549,"median":-4.395595,"eighty":-3.667586,"marketCap":11366649},{"date":"2025-04-25","current":-4.151391,"twenty":-4.835216,"median":-4.177264,"eighty":-3.720885,"marketCap":10640014},{"date":"2025-05-02","current":-3.84763,"twenty":-4.787262,"median":-4.121698,"eighty":-3.720885,"marketCap":9861476},{"date":"2025-05-09","current":-3.564121,"twenty":-4.746761,"median":-4.110889,"eighty":-3.602784,"marketCap":9134841},{"date":"2025-05-16","current":-3.361614,"twenty":-4.65953,"median":-4.080514,"eighty":-3.577234,"marketCap":8615816},{"date":"2025-05-23","current":-3.119377,"twenty":-4.520397,"median":-4.001295,"eighty":-3.54387,"marketCap":9913379},{"date":"2025-05-30","current":-2.939727,"twenty":-4.481608,"median":-3.888131,"eighty":-3.392655,"marketCap":9342451},{"date":"2025-06-06","current":-3.103045,"twenty":-4.457738,"median":-3.783334,"eighty":-3.204302,"marketCap":9861476},{"date":"2025-06-13","current":-3.037717,"twenty":-4.439261,"median":-3.7297,"eighty":-3.145507,"marketCap":9653866},{"date":"2025-06-20","current":-3.070381,"twenty":-4.403456,"median":-3.685625,"eighty":-3.125909,"marketCap":9757671},{"date":"2025-06-27","current":-2.776408,"twenty":-4.298631,"median":-3.589901,"eighty":-3.086713,"marketCap":8823426}],"updateTime":1751187620403}}}